Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1-1b Study to Evaluate the Safety, Efficacy, and Dosimetry of [177Lu]Lu-A9-0631, [225Ac]Ac-A9-0642, and [68Ga]Ga-A9-6217 in Participants With GRPR+ Tumors

NCT07661641 is registered in ClinicalTrials.gov with Alpha-9 Oncology USA Inc. as lead sponsor.

NCT NCT07661641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07661641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1-1b Study to Evaluate the Safety, Efficacy, and Dosimetry of [177Lu]Lu-A9-0631, [225Ac]Ac-A9-0642, and [68Ga]Ga-A9-6217 in Participants With GRPR+ Tumors
Lead sponsor
Alpha-9 Oncology USA Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
July 1, 2026
Completion date
December 31, 2029
Enrollment
115 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colorectal cancer, grpr-positive solid tumors, prostate cancer